Form 4: Neurogene Director Granted Stock Options

Neurogene Inc. Director Sarah B. Noonberg was granted non-qualified stock options for 12,050 shares at an exercise price of $17.64.

Summary

• Sarah B. Noonberg, a Director of Neurogene Inc. (NGNE), was granted non-qualified stock options.
• The grant is for 12,050 shares of common stock.
• The exercise price for these options is $17.64 per share.
• The options were granted on February 20, 2026, and expire on February 20, 2036.
• Vesting occurs monthly, with 1/12 of the total shares vesting each month starting March 20, 2026, and fully vesting by February 20, 2027, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard corporate governance and compensation practices aimed at aligning director incentives with company performance.

Positives

• The grant of stock options to a director aligns their interests with long-term shareholder value creation.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the options is dependent on the future stock price of Neurogene Inc. exceeding the exercise price of $17.64.
• The options are subject to forfeiture if the reporting person ceases to provide service to the issuer before full vesting.

Future Outlook

The vesting schedule for the options extends through February 20, 2027, indicating an expectation of continued service from the director during this period.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, particularly for growth-oriented companies like Neurogene, to incentivize long-term commitment and align leadership interests with shareholder returns.

Comparison to Industry Standards

• The grant of 12,050 options to a director is within typical ranges for non-executive directors at similar-sized biotech companies, often used as a component of annual compensation to encourage retention and performance.
• Companies like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY) frequently use similar equity-based compensation structures for their non-executive board members to foster alignment with long-term strategic goals.

Corporate Governance

Related Party Transactions

• Grant of non-qualified stock options to Sarah B. Noonberg, a Director of Neurogene Inc., as part of her compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. Dilution from option exercise is a minor consideration.

Next Steps

• The options will vest monthly, contingent on the director's continued service to Neurogene Inc.
• The director may choose to exercise these options at any point after vesting and before the expiration date.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information significant enough to alter an investment thesis. It reinforces alignment but does not indicate a fundamental change in the company's prospects.

Keywords

Neurogene Inc., NGNE, Form 4, Stock Options, Director Compensation, Insider Trading, Equity Grant, Beneficial Ownership